CD40 is a regulator for vascular endothelial growth factor in the tumor microenvironment of glioma

Journal of Neuroimmunology

Volumn 222, Issue 1-2, 2010, Pages 62-69

  Xie, Fang ^a,b   Shi, Qin ^c   Wang, Qin ^b   Ge, Yan ^b   Chen, Yongjing ^b   Zuo, Jianling ^c   Gu, Yongping ^a   Deng, Haizhen ^a   Mao, Hui ^b   Hu, Zhenhua ^b   Zhou, Yinghui ^a   Zhang, Xueguang ^a,b  

^a SOOCHOW UNIVERSITY   (China)

^b MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

CD40; Gliomas; Neovascularization; VEGF

Indexed keywords

BIOLOGICAL MARKER; CD40 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; VASCULOTROPIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN TISSUE; CANCER CELL CULTURE; CANCER SIZE; CANCER TISSUE; CARCINOGENESIS; CELL STIMULATION; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG TARGETING; FEMALE; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RISK ASSESSMENT; SCHOOL CHILD; STAINING; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CHILD; CYTOPLASM; FEMALE; GLIOMA; HUMANS; LIGANDS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 77952288076     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2009.12.004     Document Type: Article

References (40)

1. Aukrust P., Müller F., Ueland T., Berget T., Aaser E., Brunsvig A., Solum N.O., Forfang K., Frøland S.S., Gullestad L. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina: possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999, 100:614-620.
2. Bao S., Wu Q., Sathornsumetee S., Hao Y., Li Z., Hjelmeland A.B., Shi Q., McLendon R.E., Bigner D.D., Rich J.N. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 2006, 66:7843-7848.
3. Bergmann S., Paolo Pandolfi P. Giving blood: a new role for CD40 in tumorigenesis. J. Exp. Med. 2006, 10:1-4.
4. Biancone L., Cantaluppi V., Boccellino M., Del Sorbo L., Russo S., Albini A., Stamenkovic I., Camussi G. Activation of CD40 favors the growth and vascularization of Kaposi's sarcoma. J. Immunol. 1999, 163:6201-6208.
5. Bussolati B., Russo S., Deambrosis I., Cantaluppi V., Volpe A., Ferrando U., Camussi G. Expression of CD154 on renal cell carcinomas and effect on cell proliferation, motility and platelet-activating factor synthesis. Int. J. Cancer 2002, 100:654-661.
6. Cheng S.Y., Nagane M., Huang H.S., Cavenee W.K. Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121 and VEGF165 but not VEGF189. Proc. Natl. Acad Sci. U. S. A. 1997, 94:12081-12087.
7. Chiodoni C., Iezzi M., Guiducci C., Sangaletti S., Alessandrini I., Ratti C., Tiboni F., Musiani P., Granger D.N., Colombo M.P. Triggering CD40 on endothelial cells contributes to tumor growth. J. Exp. Med. 2006, 203:2409-2412.
8. Choudhury A., Freestone B., Patel J., Lip G.Y. Relationship of soluble CD40 ligand to vascular endothelial growth factor, angiopoietins, and tissue factor in atrial fibrillation: a link among platelet activation, angiogenesis, and thrombosisa. Chest. 2007, 132:1913-1919.
9. Clark L.B., Foy T.M., Noelle R.J. CD40 and its ligand. Adv. Immunol. 1995, 63:43-78.
10. Danese S., Scaldaferri F., Vetrano S., Stefanelli T., Graziani C., Repici A., Ricci R., Straface G., Sgambato A., Malesci A., Fiocchi C., Rutella S. Critical role of the CD40 CD40-ligand pathway in regulating mucosal inflammation-driven angiogenesis in inflammatory bowel disease. Gut 2007, 56:1248-1256.
11. Detwiller K.Y., Fernando N.T., Segal N.H., Ryeom S.W., D'Amore P., Yoon S.S. Analysis of hypoxia-related gene expression in sarcomas and effect of hypoxia on RNA interference of vascular endothelial cell growth factor A. Cancer Res. 2005, 65:5881-5889.
12. Doublier S., Ceretto M., Lupia E., Bravo S., Bussolati B., Camussi G. The proangiogenic phenotype of tumor-derived endothelial cells is reverted by the overexpression of platelet-activating factor acetylhydrolase. Clin Cancer Res. 2007, 13:5710-5718.
13. Flaxenburg J.A., Melter M., Lapchak P.H., Briscoe D.M., Pal S. The CD40-induced signaling pathway in endothelial cells resulting in the overexpression of vascular endothelial growth factor involves Ras and phosphatidylinositol 3-kinase. J. Immunol. 2004, 172:7503-7509.
14. FMelter M., Reinders M.E., Sho M., Pal S., Geehan C., Denton M.D., Mukhopadhyay D., Briscoe D.M. Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo. Blood 2000, 96:3801-3808.
15. Generali D., Buffa F.M., Berruti A., Brizzi M.P., Campo L., Bonardi S., Bersiga A., Allevi G., Milani M., Aguggini S., Papotti M., Dogliotti L., Bottini A., Harris A.L., Fox S.B. Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. J Clin Oncol. 2009, 27:227-234.
16. Grewal I.S., Foellmer H.G., Grewal K.D., Xu J., Hardardottir F., Baron J.L., Janeway C.A., Flavell R.A. Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis. Science 1996, 273:1864-1867.
17. Hill S.C., Youde S.J., Man S., Teale G.R., Baxendale A.J., Hislop A., Davies C.C., Luesley D.M., Blom A.M., Rickinson A.B., Young L.S., Eliopoulos A.G. Activation of CD40 in cervical carcinoma cells facilitates CTL responses and augments chemotherapy-induced apoptosis. J. Immunol. 2005, 174:41-50.
18. Hollenbaugh D., Mischel-Petty N., Edwards C.P., Simon J.C., Denfeld R.W., Kiener P.A., Aruffo A. Expression of functional CD40 by vascular endothelial cells. J. Exp. Med. 1995, 182:33-40.
19. Chomczynski P. A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques 1993, 15(532-534):536-537.
20. Jakobson E., Jönsson G., Björck P., Paulie S. Stimulation of CD40 in human bladder carcinoma cells inhibits anti-Fas/APO-1 (CD95)-induced apoptosis. Int. J. Cancer 1998, 77:849-853.
21. Karmann K., Hughes C.C., Schechner J., Fanslow W.C., Pober J.S. CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:4342-4346.
22. Kluth B., Hess S., Engelmann H., Schafnitzel S., Riethmüller G., Feucht H.E. Endothelial expression of CD40 in renal cell carcinoma. Cancer Res. 1997, 57:891-899.
23. Knowles H.J., Athanasou N.A. Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte-osteoclast differentiation via induction of VEGF. J Pathol. 2008, 215:56-66.
24. Larsen C.P., Elwood E.T., Alexander D.Z., Ritchie S.C., Hendrix R., Tucker-Burden C., Cho H.R., Aruffo A., Hollenbaugh D., Linsley P.S., Winn K.J., Pearson T.C. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996, 381:434-438.
25. Lim H.S., Tayebjee M.H., Tan K.T., Patel J.V., Macfadyen R.J., Lip G.Y. Is soluble CD40 ligand a mediator of angiogenesis in patients with coronary artery disease?. Thromb. Res. 2008, 122:307-313.
26. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., Scheithauer B.W., Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007, 114:97-109.
27. Mach F., Schönbeck U., Sukhova G.K., Bourcier T., Bonnefoy J.Y., Pober J.S., Libby P. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:1931-1936.
28. Oku T., Miyagawa J.G., Tjuvajev T., Sasajima T., Joshi A., Joshi R., Finn R., Claffey K.P., Blasberg R.G. Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts. Cancer Res. 1998, 58:4185-4192.
29. Ottaiano A., Pisano C., De Chiara A., Ascierto P.A., Botti G., Barletta E., Apice G., Gridelli C., Iaffaioli V.R. CD40 activation as potential tool in malignant neoplasms. Tumori 2002, 88:361-366.
30. Phipps R.P. Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system. Proc. Natl. Acad Sci. U. S. A. 2000, 97:6930-6932.
31. Reinders M.E., Sho M., Robertson S.W., Geehan C.S., Briscoe D.M. Proangiogenic function of CD40 ligand-CD40 interactions. J. Immunol. 2003, 171:1534-1541.
32. Sathornsumetee S., Hjelmeland A.B., Keir S.T., McLendon R.E., Batt D., Ramsey T., Yusuff N., Rasheed B.K., Kieran M.W., Laforme A., Bigner D.D., Friedman H.S., Rich J.N. AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma. Cancer Res. 2006, 66:8722-8730.
33. Schönbeck U., Libby P. CD40 signaling and plaque instability. Circ. Res. 2001, 89:1092-1103.
34. Tai Y.T., Podar K., Gupta D., Lin B., Young G., Akiyama M., Anderson K.C. CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells. Blood 2002, 99:1419-1427.
35. Takano S., Yoshii Y., Kondo S., Suzuki H., Maruno T., Shirai S., Nose T. Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res. 1996, 56:2185-2190.
36. Wischhusen J., Schneider D., Mittelbronn M., Meyermann R., Engelmann H., Jung G., Wiendl H., Weller M. Death receptor-mediated apoptosis in human malignant glioma cells: modulation by the CD40/CD40L system. J Neuroimmunol. 2005, 162:28-42.
37. Xie F., Wang Q., Chen Y., Gu Y., Shi Q., Ge Y., Yu G., Wu H., Mao Y., Wang X., Zhou Y., Zhang X. Characterization and application of two novel monoclonal antibodies against human OX40: costimulation of T cells and expression on tumor as well as normal gland tissues. Tissue Antigens 2006, 67:307-317.
38. Yang Y., Wilson J.M. CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. Science 1996, 273:1862-1864.
39. Zhou Z.H., Wang J.F., Wang Y.D., Qiu Y.H., Pan J.Z., Xie W., Jiang L.Y., Klein B., Zhang X.G. An agonist anti-human CD40 monoclonal antibody that induces dendritic cell formation and maturation and inhibits proliferation of a myeloma cell line. Hybridoma 1999, 18:471-478.
40. Zhuang Y., Huang J., Zhou Z., Ge Y., Fan Y., Qi C., Zhen L., Monchatre E., Edelman L., Zhang X. A novel blocking monoclonal antibody recognizing a distinct epitope of human CD40 molecule. Tissue Antigens 2005, 65:81-87.